Interest in InterMune?
Gilead Going 'MAb' Via $225M Buyout of Early Stage Arresto
By Jennifer Boggs
Tuesday, December 21, 2010
Six months after adding a kinase program to its pipeline by acquiring CGI Pharmaceuticals Inc., Gilead Sciences Inc. picked up its first monoclonal antibody product in another early stage deal, buying out privately held Arresto Biosciences Inc. for $225 million in cash plus future milestones tied to sales.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.